{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:54:31Z","timestamp":1772794471425,"version":"3.50.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.canlet.2012.08.006","type":"journal-article","created":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T14:46:10Z","timestamp":1345214770000},"page":"15-22","source":"Crossref","is-referenced-by-count":51,"title":["Selective elimination of leukemia stem cells: Hitting a moving target"],"prefix":"10.1016","volume":"338","author":[{"given":"Leslie A.","family":"Crews","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catriona H.M.","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2012.08.006_b0005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1126\/science.560061","article-title":"Primary bioassay of human tumor stem cells","volume":"197","author":"Hamburger","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.canlet.2012.08.006_b0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.bjc.6605821","article-title":"Understanding the cancer stem cell","volume":"103","author":"Bomken","year":"2010","journal-title":"Brit. J. Cancer"},{"key":"10.1016\/j.canlet.2012.08.006_b0015","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood.V68.6.1185.1185","article-title":"Clonogenic cells in acute myeloblastic leukemia","volume":"68","author":"Griffin","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0020","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2012.08.006_b0025","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2012.08.006_b0030","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1182\/blood.V89.9.3104","article-title":"Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo","volume":"89","author":"Blair","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0035","series-title":"On the Origin of Species by Means of Natural Selection, or the Preservation of Favoured Races in the Struggle for Life","author":"Darwin","year":"1859"},{"key":"10.1016\/j.canlet.2012.08.006_b0040","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1073\/pnas.0900189106","article-title":"Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation","volume":"106","author":"Abrahamsson","year":"2009","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2012.08.006_b0045","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.2415","article-title":"Stem cell gene expression programs influence clinical outcome in human leukemia","volume":"17","author":"Eppert","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2012.08.006_b0050","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-06-364182","article-title":"A clinically relevant population of leukemic CD34+CD38\u2212 cells in acute myeloid leukemia","author":"Gerber","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0055","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","article-title":"Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage","volume":"63","author":"Fialkow","year":"1977","journal-title":"Am. J. Med."},{"key":"10.1016\/j.canlet.2012.08.006_b0060","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.canlet.2012.08.006_b0065","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte\u2013macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.canlet.2012.08.006_b0070","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature04980","article-title":"Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9","volume":"442","author":"Krivtsov","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2012.08.006_b0075","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1186624","article-title":"The Wnt\/beta-catenin pathway is required for the development of leukemia stem cells in AML","volume":"327","author":"Wang","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.canlet.2012.08.006_b0080","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2012.08.006_b0085","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J. Nat. Cancer Inst."},{"key":"10.1016\/j.canlet.2012.08.006_b0090","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2012.08.006_b0095","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2012.08.006_b0100","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.canlet.2012.08.006_b0105","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR\u2013ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canlet.2012.08.006_b0110","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0115","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2012.08.006_b0120","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR\u2013ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2012.08.006_b0125","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr\u2013Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0130","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bcp.2010.04.003","article-title":"The bone marrow microenvironment as a sanctuary for minimal residual disease in CML","volume":"80","author":"Nair","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2012.08.006_b0135","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2010.31.0904","article-title":"Leukemia stem cells and microenvironment: biology and therapeutic targeting","volume":"29","author":"Konopleva","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2012.08.006_b0140","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2012.08.006_b0145","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2010.143","article-title":"Critical molecular pathways in cancer stem cells of chronic myeloid leukemia","volume":"24","author":"Chen","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2012.08.006_b0150","doi-asserted-by":"crossref","DOI":"10.1007\/s11899-012-0117-2","article-title":"Curing chronic myeloid leukemia","author":"Rea","year":"2012","journal-title":"Curr. Hematol. Malignancy Rep."},{"key":"10.1016\/j.canlet.2012.08.006_b0155","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1182\/blood.V83.5.1179.1179","article-title":"BCR\u2013ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death","volume":"83","author":"McGahon","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0160","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1182\/blood.V91.7.2415","article-title":"BCR\u2013ABL delays apoptosis upstream of procaspase-3 activation","volume":"91","author":"Dubrez","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0165","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1182\/blood.V91.5.1700","article-title":"Bcr\u2013Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3","volume":"91","author":"Amarante-Mendes","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0170","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.onc.1201490","article-title":"BCR\u2013ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner","volume":"16","author":"Cambier","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2012.08.006_b0175","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.leu.2403724","article-title":"Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli","volume":"19","author":"Holtz","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2012.08.006_b0180","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0185","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nm.2713","article-title":"A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer","volume":"18","author":"Ng","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2012.08.006_b0190","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-08-0144","article-title":"Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy","volume":"15","author":"Kang","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.08.006_b0195","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3322\/canjclin.55.3.178","article-title":"Targeting apoptosis pathways in cancer therapy","volume":"55","author":"Ghobrial","year":"2005","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.canlet.2012.08.006_b0200","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/leu.2011.285","article-title":"Activation of apoptosis signaling eliminates CD34(+) progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors","volume":"26","author":"Mak","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2012.08.006_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2012.01.004","article-title":"ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(\u2212) population to imatinib","author":"Airiau","year":"2012","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.canlet.2012.08.006_b0210","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"Aichberger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0215","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/jid.2008.445","article-title":"A Wnt survival guide: from flies to human disease","volume":"129","author":"Chien","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.canlet.2012.08.006_b0220","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nature03319","article-title":"Wnt signalling in stem cells and cancer","volume":"434","author":"Reya","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2012.08.006_b0225","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2012.08.006_b0230","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2012.08.006_b0235","doi-asserted-by":"crossref","first-page":"17967","DOI":"10.1073\/pnas.0808303105","article-title":"BCR\u2013ABL-transformed GMP as myeloid leukemic stem cells","volume":"105","author":"Minami","year":"2008","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2012.08.006_b0240","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.emboj.7601485","article-title":"Bcr\u2013Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation","volume":"26","author":"Coluccia","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/j.canlet.2012.08.006_b0245","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.canlet.2011.08.002","article-title":"Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65 \u2013 a novel Wnt\/beta-catenin signaling inhibitor","volume":"312","author":"Nagao","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2012.08.006_b0250","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacological inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Heidel","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2012.08.006_b0255","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2012.08.006_b0260","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1073\/pnas.0504337103","article-title":"Phosphoinositide 3-kinase and Akt are essential for Sonic hedgehog signaling","volume":"103","author":"Riobo","year":"2006","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2012.08.006_b0265","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/84282","article-title":"Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation","volume":"2","author":"Bhardwaj","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2012.08.006_b0270","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.devcel.2005.01.010","article-title":"Hedgehog signaling is required for adult blood stem cell formation in zebrafish embryos","volume":"8","author":"Gering","year":"2005","journal-title":"Dev. Cell"},{"key":"10.1016\/j.canlet.2012.08.006_b0275","doi-asserted-by":"crossref","first-page":"14134","DOI":"10.1073\/pnas.0604568103","article-title":"Hedgehog modulates cell cycle regulators in stem cells to control hematopoietic regeneration","volume":"103","author":"Trowbridge","year":"2006","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2012.08.006_b0280","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0896-6273(03)00561-0","article-title":"Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches","volume":"39","author":"Machold","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.canlet.2012.08.006_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/dbio.1998.9103","article-title":"Essential role for Sonic hedgehog during hair follicle morphogenesis","volume":"205","author":"Chiang","year":"1999","journal-title":"Dev. Biol."},{"key":"10.1016\/j.canlet.2012.08.006_b0290","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr\u2013Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2012.08.006_b0295","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2012.08.006_b0300","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1126\/science.280.5369.1603","article-title":"Teratogen-mediated inhibition of target tissue response to Shh signaling","volume":"280","author":"Cooper","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.canlet.2012.08.006_b0305","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1242\/dev.125.18.3553","article-title":"The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction","volume":"125","author":"Incardona","year":"1998","journal-title":"Development"},{"key":"10.1016\/j.canlet.2012.08.006_b0310","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/383407a0","article-title":"Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function","volume":"383","author":"Chiang","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2012.08.006_b0315","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ng1196-357","article-title":"Mutations in the human Sonic Hedgehog gene cause holoprosencephaly","volume":"14","author":"Roessler","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2012.08.006_b0320","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ng1196-353","article-title":"Identification of Sonic hedgehog as a candidate gene responsible for holoprosencephaly","volume":"14","author":"Belloni","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2012.08.006_b0325","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2009.03.007","article-title":"Mechanisms of hedgehog pathway activation in cancer and implications for therapy","volume":"30","author":"Scales","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.canlet.2012.08.006_b0330","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJMoa0902903","article-title":"Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449","volume":"361","author":"Rudin","year":"2009","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.canlet.2012.08.006_b0335","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"Von Hoff","year":"2009","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.canlet.2012.08.006_b0340","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-11-0923","article-title":"Hedgehog fights back: mechanisms of acquired resistance against smoothened antagonists","volume":"71","author":"Metcalfe","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.08.006_b0345","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0065-230X(04)91004-4","article-title":"Histone deacetylase inhibitors","volume":"91","author":"Marks","year":"2004","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.canlet.2012.08.006_b0350","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2012.08.006_b0355","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.1038\/sj.onc.1207893","article-title":"Histone deacetylase inhibitors specifically kill nonproliferating tumour cells","volume":"23","author":"Burgess","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2012.08.006_b0360","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","article-title":"Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr\u2013Abl-expressing human leukemia cells","volume":"108","author":"Fiskus","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0365","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","article-title":"Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells","volume":"12","author":"Fiskus","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.08.006_b0370","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr\u2013Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.08.006_b0375","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","article-title":"Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr\u2013Abl-positive human acute leukemia cells","volume":"101","author":"Nimmanapalli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0380","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2012.08.006_b0385","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2012.08.006_b0390","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Chen","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2012.08.006_b0395","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1038\/onc.2011.3","article-title":"Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen","volume":"30","author":"Tauchi","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2012.08.006_b0400","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2012.08.006_b0405","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0410","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nbt1350","article-title":"Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region","volume":"25","author":"Ishikawa","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2012.08.006_b0415","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0420","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.08.006_b0425","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.leu.2402608","article-title":"Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins","volume":"16","author":"Konopleva","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2012.08.006_b0430","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","article-title":"IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development","volume":"20","author":"Reynaud","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2012.08.006_b0435","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/leu.2008.290","article-title":"Miscreant myeloproliferative disorder stem cells","volume":"22","author":"Jamieson","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2012.08.006_b0440","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","article-title":"CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells","volume":"7","author":"Jin","year":"2008","journal-title":"Mol. Cancer Therap."},{"key":"10.1016\/j.canlet.2012.08.006_b0445","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.stem.2007.08.001","article-title":"Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4","volume":"1","author":"Todaro","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2012.08.006_b0450","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.stem.2009.12.010","article-title":"Key roles for transforming growth factor beta in melanocyte stem cell maintenance","volume":"6","author":"Nishimura","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2012.08.006_b0455","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ccr.2006.11.020","article-title":"A perivascular niche for brain tumor stem cells","volume":"11","author":"Calabrese","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2012.08.006_b0460","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2010.09.043","article-title":"DNA damage-mediated induction of a chemoresistant niche","volume":"143","author":"Gilbert","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2012.08.006_b0465","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nbt.1607","article-title":"Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML","volume":"28","author":"Saito","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2012.08.006_b0470","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 eradicates human acute myeloid leukemic stem cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2012.08.006_b0475","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nm1489","article-title":"Requirement for CD44 in homing and engraftment of BCR\u2013ABL-expressing leukemic stem cells","volume":"12","author":"Krause","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2012.08.006_b0480","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1084\/jem.20072513","article-title":"CXCR4 is required for the quiescence of primitive hematopoietic cells","volume":"205","author":"Nie","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2012.08.006_b0485","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.immuni.2006.10.016","article-title":"Maintenance of the hematopoietic stem cell pool by CXCL12\u2013CXCR4 chemokine signaling in bone marrow stromal cell niches","volume":"25","author":"Sugiyama","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2012.08.006_b0490","article-title":"Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib","author":"Weisberg","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2012.08.006_b0495","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2011-04-347518","article-title":"Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia","volume":"119","author":"O\u2019Callaghan","year":"2012","journal-title":"Blood"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383512004776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383512004776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T19:39:07Z","timestamp":1643225947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383512004776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0304383512004776"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2012.08.006","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}